Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This partially-blind, placebo controlled study is a Phase 1b study using an investigational vaccine, NDV-3, directed against Staphylococcus aureus and Candida sp. This study will compare NDV-3 administered with or without alum delivered intramuscularly (IM) at one dose level. It will also evaluate a lower dose of NDV-3 without alum delivered intradermally (ID) compared to placebo delivered ID.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nasal Antisepsis for C. Auris Prevention

NCT06282510

Candida Auris Infection Colonization, Asymptomatic

RECRUITING PHASE4

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862

Candidemia Mycoses Fungal Infection +2 more

COMPLETED PHASE2

Vulvovaginal Candidiasis in Canadian Females

NCT04930107

Candidiasis, Vulvovaginal

RECRUITING EARLY_PHASE1

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

NCT00056368

Candidiasis

COMPLETED PHASE3

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

NCT00037219

Candidiasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preclinical studies in mice have established that several members of the Als family of proteins induce a protective immune response in mice and allow high survival rates following challenge with highly virulent doses of either Candida or S. aureus. Als3 (the antigen in the NDV-3 investigational vaccine) is the most effective member of the Als protein family in protecting mice from challenge with either Candida or S. aureus. The first Phase 1 study enrolled 40 healthy subjects that received placebo (N=10), 1 dose (N=30) or 2 doses (N=19) of the NDV-3 vaccine administered intramuscularly (IM). The vaccine was well tolerated and highly immunogenic. This study will evaluate the safety, tolerability and immunogenicity of one dose of NDV-3 vaccine formulated with and without alum given IM and also a lower dose without alum given intradermally (ID). Subjects will have follow-up visits to assess the safety tolerability and immune responses at selected time points up to 90 days post-vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Staphylococcal Infections Yeast Infections Candidiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NDV-3 vaccine with alum IM

300 ug Als3 and 0.5 mg Al as alum in PBS per dose, one dose administered IM

Group Type ACTIVE_COMPARATOR

NDV-3 vaccine with alum IM

Intervention Type BIOLOGICAL

One dose administered IM

NDV-3 vaccine without alum IM

300 ug Als3 in PBS per dose, one dose administered IM

Group Type ACTIVE_COMPARATOR

NDV-3 vaccine without alum IM

Intervention Type BIOLOGICAL

One dose administered IM

Placebo IM

0.5 mg Al as alum in PBS per dose, one dose administered IM

Group Type PLACEBO_COMPARATOR

Placebo with alum IM

Intervention Type BIOLOGICAL

One dose administered ID

NDV-3 vaccine without alum ID

30 ug Als3 in PBS per dose, one dose administered ID

Group Type ACTIVE_COMPARATOR

NDV-3 vaccine without alum ID

Intervention Type BIOLOGICAL

One dose administered ID

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NDV-3 vaccine with alum IM

One dose administered IM

Intervention Type BIOLOGICAL

NDV-3 vaccine without alum IM

One dose administered IM

Intervention Type BIOLOGICAL

Placebo with alum IM

One dose administered ID

Intervention Type BIOLOGICAL

NDV-3 vaccine without alum ID

One dose administered ID

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed of the nature of the study and have agreed to and are able to read, review, and sign the informed consent document prior to screening. The informed consent document will be written in English, therefore the volunteer must have the ability to read and communicate in English.
2. Completed the screening process (as described in this protocol) within 28 days prior to dosing.
3. Healthy male and female volunteers 18-50 years of age, inclusive, at the time of dosing.
4. No clinically significant deviation from normal as judged by the investigator(s) in the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems), vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and by general observations.
5. Female volunteers must be one of the following:

* of childbearing potential and practicing an acceptable method of birth control as judged by the Investigator(s)
* naturally postmenopausal (no menses) for at least 1 year and has a documented FSH level ≥ 40 mIU/mL
* surgically postmenopausal (bilateral oophorectomy or hysterectomy)
* sterile (surgically \[bilateral tubal ligation\] or the Essure® Procedure) Female volunteers that are surgically sterile or surgically postmenopausal must provide documentation of the bilateral tubal ligation, bilateral oophorectomy, or hysterectomy prior to dosing or the volunteer must agree to use a medically acceptable method of birth control. The Essure® Procedure must have been inserted at least 3 months prior with documentation of the Essure® confirmation test prior to Period I dosing. If the procedure was inserted less than 3 months prior to Period I dosing or proper documentation of the confirmation test is not provided, the volunteer must agree to use an additional medically acceptable method of birth control.

Exclusion Criteria

1. Reports receiving any investigational drug, investigational vaccine, or investigational device within 30 days prior to dosing.
2. Reports any presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined by the Investigator(s).
3. Clinical laboratory test values outside the accepted range.
4. When confirmed upon additional testing, demonstrates a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
5. Demonstrates a positive drug screen for non-prescription drugs.
6. Reports a clinically significant illness during the 28 days prior to dosing (as determined by the Investigator\[s\]).
7. Reports a history of allergic response(s) to nickel or anaphylaxis (or other serious reactions) to aluminum.
8. Reports receiving any live attenuated vaccine including FluMist® within 6 weeks prior to dosing or any licensed inactivated vaccine within 3 weeks prior to dosing.
9. Reports the use of any immunosuppressive drugs, including systemic corticosteroids, within 4 weeks prior to dosing.
10. Reports the use of any medications or treatments that may alter immune responses to the study vaccine within 3 weeks prior to dosing (eg, cyclosporine, tacrolimus, cytotoxic drugs, immune globulin, Bacillus Calmette-Guerin \[BCG\], monoclonal antibodies, radiation therapy).
11. Reports a history of clinically significant allergies including food or drug allergies or anaphylaxis (or other serious reactions) to vaccines.
12. Reports a history of drug or alcohol addiction or abuse within the past year.
13. Reports receiving any blood products within 3 months prior to dosing and throughout the study.
14. Reports donating blood within 28 days prior to dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
15. Reports donating plasma (e.g. plasmapheresis) within 14 days prior to dosing. All subjects will be advised not to donate plasma for four weeks after completing the study.
16. Demonstrates, in the opinion of study staff, veins unsuitable for repeated venipuncture (e.g. veins difficult to locate, access, or puncture; veins with a tendency to rupture during or after puncture).
17. Pregnant, lactating, breastfeeding, or intends to become pregnant over the course of the study.
18. Demonstrates a positive pregnancy screen.
19. Reports smoking or using tobacco products or is currently using nicotine products (patches, gums, etc). Thirty (30) days abstinence prior to dosing is required.
20. Any other medical and/or social (e.g. uncooperative or non-compliant) reason which, in the opinion of the investigator(s), would prevent participation in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes